Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

History

CytoSorb® is a first-in-class, polymer-based blood purification technology with multiple therapeutic applications. In 2008, the Company began to focus heavily on developing immunotherapy technologies to address inflammation-driven catastrophic diseases. Since then, the Company has developed a wide array of products such as the CytoSorb® cartridge-based blood purification system and its line of continuous renal replacement therapies.

Mission

CytoSorbents is dedicated to improving the health of critical care patients; reducing oxidative stress and inflammation through products that capture and remove toxins from the bloodstream.

Vision

CytoSorbents is striving to become the global leader in critical care immunotherapy for premature infants and critically ill patients worldwide.

Key Team

Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. (Chief Medical Officer)

Ms. Terri Anne Powers M.B.A. (VP of Investor Relations & Corp. Communications)

Mr. Christopher Cramer MBA, MS (VP of Bus. Devel.)

Dr. Robert H. Bartlett M.D. (Co-Chairman of Cardiac Surgery Advisory Board & Consultant)

Dr. Christian Steiner M.D. (Exec. VP of Sales & Marketing)

Recognition and Awards

CytoSorbents has won multiple industry awards, including being chosen as Top 100 Most Innovative Companies from South Jersey Biz Magazine, Top Innovator Award from the New Jersey Technology Council, and Technology of the Year Award from the American Association of Critical Care Nurses.